The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

S100B is frequently elevated in malignant melanoma. A regulatory mechanism was uncovered here in which elevated S100B lowers mRNA and secreted protein levels of interleukin-6 (IL6) and inhibits an autocrine loop whereby IL6 activates STAT3 signaling. Our results showed that S100B affects IL6 expression transcriptionally. S100B was shown to form a calcium-dependent protein complex with the p90 ribosomal S6 kinase (RSK), which in turn sequesters RSK into the cytoplasm. Consistently, S100B inhibition was found to restore phosphorylation of a nuclear located RSK substrate, CREB, which is a potent transcription factor for IL6 expression. Thus, elevated S100B reduces IL6-STAT3 signaling via RSK signaling pathway in malignant melanoma. Indeed, the elevated S100B levels in malignant melanoma cell lines correspond to low levels of IL6 and p-STAT3.

Cite

CITATION STYLE

APA

Alasady, M. J., Terry, A. R., Pierce, A. D., Cavalier, M. C., Blaha, C. S., Adipietro, K. A., … Hay, N. (2021). The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling. PLoS ONE, 16(8 August). https://doi.org/10.1371/journal.pone.0256238

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free